KeyCorp (NYSE:KEY) 2026 Conference February 10, 2026 08:50 AM ET Company ParticipantsChris Gorman - Chairman and CEOConference Call ParticipantsEbrahim Poonawala - Equity Research AnalystEbrahim PoonawalaSo, for our first regional bank presentation, as has been tradition over the last few years, we have Chris Gorman, Chairman and CEO KeyCorp. So, Chris, thank you so much for joining us.Chris GormanSo, check, check. So it's great to be here, and we always appreciate kind of kicking off your conference. It's ...

Summary of Evommune's EVO301 Topline Phase 2A Results Conference Call Company Overview - **Company**: Evommune - **Product**: EVO301, a biologic targeting IL-18 for the treatment of moderate to severe atopic dermatitis - **Industry**: Biopharmaceuticals, specifically focused on chronic inflammatory diseases Key Points and Arguments Positive Clinical Results - EVO301 demonstrated unequivocally positive data in the Phase 2A proof-of-concept trial for atopic dermatitis, meeting its primary endpoint decisively [3][10] - The trial showed a Bayesian posterior probability of 99.76% that the true difference between EVO301 and placebo in the percent change from baseline at EASI was at least 8% [10] - At week 12, patients receiving EVO301 experienced a 55% mean reduction in EASI compared to 22% in the placebo group [17] - 23% of patients achieved an IGA of 0 or 1 versus 0% in the placebo group [19] Safety Profile - EVO301 was well-tolerated with no serious or severe adverse events related to the study drug [10][23] - No discontinuations due to treatment-related adverse events were reported [23] Mechanism of Action - EVO301 is designed as a long-acting fusion protein that neutralizes IL-18, which plays a key role in various immune processes and chronic inflammatory diseases [8][9] - The drug targets multiple inflammatory pathways, making it potentially more effective for heterogeneous diseases like atopic dermatitis [9][22] Future Development Plans - Evommune plans to advance EVO301 into a Phase 2B study with a subcutaneous formulation, leveraging insights from the Phase 2A study [25][26] - The Phase 2B study will likely include more doses and a longer duration to optimize efficacy [31][32] Market Context - Atopic dermatitis affects approximately 13 million Americans, with around 40% of patients not adequately controlled by existing therapies [24] - There is a significant unmet need for effective treatments, highlighting the potential market opportunity for EVO301 [24] Pipeline Expansion - Evommune is also evaluating additional indications for IL-18, including ulcerative colitis and other chronic inflammatory diseases [26][78] - The company believes that the mechanism of IL-18 modulation could lead to a broader pipeline of therapies [78] Additional Important Information - The trial was randomized, double-blind, and placebo-controlled, enrolling 70 patients across 12 sites in Australia and New Zealand [12][15] - The study design optimized for early clinical signal detection using Bayesian analysis [12] - The results from the Phase 2A trial will be presented at a future scientific conference [22] This summary encapsulates the critical findings and strategic direction of Evommune regarding EVO301, emphasizing its potential impact on the treatment landscape for atopic dermatitis and other inflammatory diseases.

The Williams Companies (NYSE:WMB) 2026 Investor Day February 10, 2026 08:30 AM ET Company ParticipantsChad Zamarin - President and CEODanilo Juvane - VP of Investor RelationsJohn Porter - EVP and CFOLarry Larsen - EVP and COORob Wingo - EVP of Corporate Strategic DevelopmentNone - Video NarratorConference Call ParticipantsAmit Tucker - Equity Research AnalystCraig Shere - Equity Research AnalystGabriel Moreen - Managing Director and Senior Equity Research AnalystJason Gabelman - Equity Research AnalystJean ...

Nektar Therapeutics (NasdaqCM:NKTR) Conference Call Summary Company Overview - **Company**: Nektar Therapeutics - **Focus**: Development of Rezpegaldesleukin (ResPEG) for the treatment of atopic dermatitis and other conditions Key Points from the Conference Call Industry and Product Insights - **Therapeutic Area**: Atopic dermatitis, with a focus on patients with comorbid asthma, which represents 25% of the overall population [3][12] - **Mechanism of Action**: ResPEG utilizes a novel TREG mechanism to promote immune resolution, differentiating it from traditional cytokine-blocking therapies [8][9] - **Clinical Trials**: Phase 2b Resolve AD study results were discussed, highlighting the efficacy and safety of ResPEG over a 36-week maintenance period [3][15] Clinical Data Highlights - **Efficacy Results**: - 74% of patients on the 24 microgram per kilogram monthly regimen maintained their EASI-75 response at week 52 [22] - 80% of patients on the monthly dosing regimen maintained an EZ90 response, compared to 78% on the quarterly regimen [23] - New responders were identified, with 41% and 40% of non-responders converting to vIGA responders at the end of 52 weeks for monthly and quarterly regimens, respectively [29] - A five-fold increase in patients achieving complete disease clearance (EASI-100) was observed, with 30% of patients achieving this by the end of 52 weeks [31] Safety Profile - **Adverse Events**: - Discontinuation due to adverse events was low at 3.5%, with no new safety signals identified [32] - Injection site reactions (ISRs) were the most common adverse events, with a frequency of 0.7% leading to treatment discontinuation [32][70] - The incidence of ISRs decreased during the maintenance phase compared to induction [33] Future Development Plans - **Phase 3 Trials**: Plans to initiate Phase 3 trials in Q2 2026, targeting a BLA submission in 2029 [5][36] - **Patient Population**: Trials will include biologic-naïve patients and those who have received prior biologics or JAK inhibitors [37] Competitive Landscape - **Comparison with Dupilumab**: ResPEG's maintenance efficacy was shown to be comparable or superior to Dupilumab, particularly in maintaining vIGA responses [25][26] - **Market Positioning**: ResPEG is positioned as a first-line treatment option, especially for patients with comorbid asthma, which is a significant differentiator from other therapies [44][52] Expert Opinions - **Clinical Adoption**: Experts expressed optimism about using ResPEG as a first-line treatment due to its efficacy and safety profile, particularly for difficult-to-treat patients [42][48] Upcoming Milestones - **Data Presentations**: Additional data from the Resolve AD study and other ongoing studies are expected to be presented at medical meetings in the coming year [38] Conclusion Nektar Therapeutics is advancing its clinical development of ResPEG for atopic dermatitis, demonstrating promising efficacy and safety data. The upcoming Phase 3 trials and the potential for a BLA submission in 2029 position the company favorably in the competitive landscape of dermatological therapies.

Bank of America (NYSE:BAC) 2026 Conference February 10, 2026 08:00 AM ET Company ParticipantsBrian Moynihan - Chairman and CEOIbrahim Poonawala - Head of North American Banks ResearchIbrahim PoonawalaWe'll go ahead and get started. Welcome to Bank of America's 34th Annual Financial Services Conference. I'm Ibrahim Poonawala, Head of North American Banks Research at BofA, and it's a pleasure to welcome you all. I would like to thank all the management teams and investors for their partnership, which has help ...

The Goldman Sachs Group (NYSE:GS) 2026 Conference February 10, 2026 08:00 AM ET Company ParticipantsDavid Solomon - Chairman and CEOModeratorMaybe let's start at the top in terms of your strategic priorities. You've continued to make significant progress against them. You laid out some of your plans in the recent strategic update. Of course, as everybody in the room knows, the stock has meaningfully outperformed many of your peers. Maybe let's talk about some of the most significant changes over both the lo ...

Koninklijke Philips (NYSE:PHG) 2026 Capital Markets Day February 10, 2026 05:55 AM ET Company ParticipantsBert van Meurs - EVP and Chief Business Leader of Image Guided TherapyBert van Meurs - EVP and and Chief Business Leader of Image Guided TherapyCharlotte Hanneman - CFODavid Adlington - Managing Director and Head of European Medtech and Services ResearchDeeptha Khanna - EVP and Chief Business Leader of Personal HealthDurga Doraisamy - Head of Investor RelationsEd Ridley-Day - Head of Global MedTech and ...

Summary of TMX Group Conference Call Company Overview - **Company**: TMX Group - **Industry**: Canadian capital markets ecosystem, including exchanges, derivatives markets, and data services - **Key Components**: - Blue chip and junior equity exchanges - Montreal Exchange for derivatives - Clearing and settlement infrastructure - International operations including TradePort in the UK and VettaFi in the U.S. [3][4] Core Business Insights - **Recurring Revenue Target**: Long-term target is to achieve two-thirds of revenue from recurring sources, currently at 52% down from 55% due to strong performance in trade business [5][6] - **International Revenue**: 51% of business is now outside Canada, with a target of 50% from Global Insights, currently at 44% [6] - **Trayport Performance**: Trayport, a key growth area, showed 12% growth in constant currency, down from 17% in the previous year, attributed to market maturity and lack of volatility [7][11] - **Growth Opportunities**: Expansion in U.S. gas and power markets, early-stage growth in Japan, and transitioning oil markets to on-screen trading [13][14] VettaFi and Global Insights - **VettaFi Growth**: Achieved 25% year-over-year growth in 2025, with 13% from organic growth and 12% from acquisitions [22] - **Assets Under Management**: Increased from CAD 32 billion to over CAD 80 billion since acquisition [24] - **Product Development**: Focus on expanding indices and asset classes, including fixed-income products and distribution capabilities [23] AI and Technology Integration - **AI as a Beneficiary**: TMX Group views itself as a net beneficiary of AI, leveraging proprietary data platforms to enhance product offerings [28][30] - **Efficiency Gains**: AI tools are being used to improve development speed and product testing, allowing for better market delivery [35][36] - **Revenue Opportunities**: AI is expected to enhance client products and self-service capabilities, with over 90% adoption of AI tools across the company [38][39] Trading Business Insights - **Derivatives Market**: Experienced over 30% growth last year, with open interest up 20% despite a 5-6% decline in total volume year-over-year [42][43] - **Options on ETFs**: Continued adoption is a significant growth driver, with regulatory efforts to expand capacity [44] - **Canadian Equities Landscape**: TMX Group maintains a strong competitive position despite challenges from international players like CBOE [51][52] Capital Formation and IPO Pipeline - **Strong Financing Activity**: 60% year-over-year increase in financing activity, with a deep pipeline of companies ready for IPOs [66][68] - **Market Confidence**: Despite recent market volatility, there is optimism about the ability to execute good deals [68] Expense Management and M&A Strategy - **Expense Growth**: Targeting 5% year-over-year expense growth, with a focus on positive operating leverage [73][74] - **M&A as Strategy Accelerator**: TMX Group actively seeks acquisitions that align with its growth strategy, focusing on enhancing data capabilities and market reach [76][77] Conclusion - **Overall Outlook**: TMX Group is positioned for continued growth through strategic expansion, technology integration, and a robust IPO pipeline, while maintaining a focus on operational efficiency and market leadership in the Canadian capital markets [66][68][76]

KeyCorp (NYSE:KEY) 2026 Conference February 09, 2026 03:30 PM ET Company ParticipantsKen Gavrity - Head of Commercial BankingConference Call ParticipantsErika Penala - Equity Research AnalystErika PenalaAll right, good afternoon, everybody. So, you know, rounding off the corporate presentations today, we have KeyCorp, and we had Ken Gavrity. He is the head of the commercial bank, and before he sits down with me for a fireside chat, he wanted to share a few slides. Ken, thank you for coming.Ken GavrityPerfec ...

Unum Group 2026 Conference Call Summary Company Overview - **Company**: Unum Group (NYSE: UNM) - **Date**: February 09, 2026 - **Speakers**: Rick McKenney (CEO), Steve Zabel (CFO) Key Points 2026 Outlook - Unum expects top-line growth in premium between **4%-7%** off a **$10 billion** base, leading to an **earnings per share (EPS)** growth of **8%-12%** [2][3] - The company plans to return approximately **100%** of its earnings to shareholders through dividends and share repurchases [3][4] Group Disability Business - The group disability market is competitive but rational in pricing, with Unum's strong positioning due to investments in employer HRIS systems [6][7] - The benefit ratio for group disability was **62.5%** in 2025, with expectations to adjust prices leading to a target range of **62%-64%** for 2026 [9][10] - Historical benefit ratios were in the low **70s** pre-pandemic, with normalization expected around **65%** over the next **2-3 years** [11][12] Closed Block Strategy - Unum has fully closed its Closed Block, which will now be reported below the line as a special item, isolating core business performance [15][20] - The company maintains a **$2.2 billion** protection behind the Closed Block, with no additional capital planned for this segment [22][24] Leave Management - Unum has invested in leave management platforms, managing over **2 million** people on its leave platform, which integrates well with short-term and long-term disability offerings [35][36] - The proliferation of new leave types has created a demand for effective leave management solutions, positioning Unum favorably in the market [33][34] Technology and AI Integration - Unum has developed various technologies, including HR Connect and Agent Assist, to enhance customer experience and operational efficiency [39][40] - AI is being utilized to improve customer interactions and internal efficiencies, with ongoing investments in AI solutions [50][51] Capital Deployment - In 2025, Unum repurchased **$1 billion** in shares and paid **$300 million** in dividends, with plans for similar capital deployment in 2026 [71][72] - The company ended 2025 with a **440 RBC** and **$2.2 billion** in cash, indicating a strong capital position [73][78] Market Sentiment and Economic Outlook - Unum's growth is expected to continue despite potential economic headwinds, with a focus on maintaining a strong benefits package for employees [62][63] - The company anticipates a **4%-7%** top-line growth rate, driven by wage inflation and payroll growth [57][58] Competitive Dynamics - The competitive landscape in group life and AD&D remains stable, with Unum focusing on delivering comprehensive packages that include leave management and voluntary benefits [91][92] Future Growth Opportunities - Unum is exploring inorganic growth opportunities, particularly in the UK and Poland, to expand its scale and capabilities [90][87] - The company aims to leverage technology and services to enhance customer experience and drive growth [88][89] Conclusion Unum Group is positioned for steady growth in 2026, with a strong focus on capital return to shareholders, strategic investments in technology, and a commitment to enhancing its core business offerings. The company remains optimistic about its market position and growth potential despite economic uncertainties.